Cognito Therapeutics
Cognito Therapeutics

Cognito Therapeutics

Measured by AhrefsDR49Ahrefs DR: 49/100. Above median. Measured by Ahrefs. Median 44.Measured by StartupHub.aiAgent33Agent Readiness: 33/100. Below median. Measured by StartupHub.ai. Median 41.Measured by Google PageSpeedSpeed71Site Speed: 71/100. Above median. Measured by Google PageSpeed. Median 62.Measured by StartupHub.aiTrust82Data Trust: 82/100. Top 25%. Measured by StartupHub.ai. Median 61.

Developing a novel therapeutic approach for Alzheimer's disease.

2011ActiveBoston, USA

About

Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.

Key facts

Website
cognitotx.com
Headquarters
Boston, Massachusetts, USA
Founded
2011
Total funding
$213M (Series C)
Business model
B2B2C

Funding rounds

Funding rounds raised by Cognito Therapeutics
DateRoundAmountLead investors
5 Mar 2026Series C$105M
29 Jan 2024Series B Extension$35M
22 Mar 2023Series B$73MFoundersX Ventures

Tech stack

Detected on cognitotx.com, last scanned 2 Nov 2026.

Analytics
Google Tag Manager
Support
HubSpot
CMS / Builders
Webflow
CDN
Cloudflare
Email provider
Microsoft 365
Video / media
Vimeo

Cognito Therapeutics scores 49. Does yours?

That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.

Add first review

Frequently asked

Is Cognito Therapeutics trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Cognito Therapeutics is 82 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Cognito Therapeutics raised?

Cognito Therapeutics has raised a total of $213M in funding. The most recent round on record is Series C.

Public record

SEC filings, insider activity, nonprofit links and pay benchmarks for Cognito Therapeutics